At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Not Yet Opened 03-25 16:08:32
14.440
+0.630
+4.56%
High14.540Low13.810Vol1.24M
Open13.810D1 Closing13.810Amplitude5.29%
Mkt Cap15.32BTradable Cap15.32BTotal Shares1.06B
T/O17.81MT/O Rate0.12%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Tiger Newspress  ·  03-24 09:46
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026
Reuters  ·  03-17
BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026
Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets
Reuters  ·  03-17
Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets
ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models
Stock News  ·  03-17
ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models
Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026
THOMSON REUTERS  ·  03-17
Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026
Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026
Reuters  ·  03-17
Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026
HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.
Tiger Newspress  ·  03-17
HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.
BRIEF-Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity
Reuters  ·  03-10
BRIEF-Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity
Ascletis Pharma Inc - Asc30 Achieves 7.5% Placebo-Adj Mean Weight Loss at Week 16 After Three Monthly Doses
THOMSON REUTERS  ·  03-10
Ascletis Pharma Inc - Asc30 Achieves 7.5% Placebo-Adj Mean Weight Loss at Week 16 After Three Monthly Doses
Ascletis Pharma Inc - No Discontinuations Due to Adverse Events for Asc30 or Placebo
THOMSON REUTERS  ·  03-10
Ascletis Pharma Inc - No Discontinuations Due to Adverse Events for Asc30 or Placebo
Ascletis Pharma Inc - Asc30 Demonstrates Safety Profile Consistent With Glp-1 Drug Class
THOMSON REUTERS  ·  03-10
Ascletis Pharma Inc - Asc30 Demonstrates Safety Profile Consistent With Glp-1 Drug Class
Ascletis Pharma Inc: Asc30 Phase Ii Study Achieved Its Primary Endpoint
THOMSON REUTERS  ·  03-10
Ascletis Pharma Inc: Asc30 Phase Ii Study Achieved Its Primary Endpoint
Ascletis Pharma Inc - Asc30 Maintains Weight Loss for Four Months After Final Monthly Dose
THOMSON REUTERS  ·  03-10
Ascletis Pharma Inc - Asc30 Maintains Weight Loss for Four Months After Final Monthly Dose
Ascletis Announces Positive Topline Results From U.S. Phase Ii, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule Glp-1R Agonist Asc30 for Obesity
THOMSON REUTERS  ·  03-10
Ascletis Announces Positive Topline Results From U.S. Phase Ii, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule Glp-1R Agonist Asc30 for Obesity
ASCLETIS-B's Long-Acting GLP-1 Candidate Shows Promising Weight Loss in U.S. Phase II Trial
Stock News  ·  03-10
ASCLETIS-B's Long-Acting GLP-1 Candidate Shows Promising Weight Loss in U.S. Phase II Trial
Ascletis reports Phase II ASC30 depot achieves 8% placebo-adjusted weight loss at week 16
Reuters  ·  03-10
Ascletis reports Phase II ASC30 depot achieves 8% placebo-adjusted weight loss at week 16
Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities
Bulletin Express  ·  03-03
Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities
Hong Kong Market Enters Era of Pricing Power Stratification as Mainland's 1.41 Trillion HKD Southbound Flows Anchor Market While Korean Retail Investors Ignite Speculative Activity
Stock News  ·  02-13
Hong Kong Market Enters Era of Pricing Power Stratification as Mainland's 1.41 Trillion HKD Southbound Flows Anchor Market While Korean Retail Investors Ignite Speculative Activity
Assessing Ascletis Pharma (SEHK:1672) Valuation After New Obesity And Acne Pipeline Updates
Simply Wall St.  ·  02-11
Assessing Ascletis Pharma (SEHK:1672) Valuation After New Obesity And Acne Pipeline Updates
Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies
MT Newswires Live  ·  02-11
Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--